Back
HCV Treatment 
AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates
AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates
AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates
- Details
- Category: HCV Treatment
- Published on Tuesday, 15 November 2011 00:00
- Written by Liz Highleyman
Several studies at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco showed that adding experimental direct-acting antiviral (DAA) agents to pegylated interferon plus ribavirin increases virological response rates for people with chronic hepatitis C.
BI 201335 Performs Well with Standard Therapy
TMC435 + Pegylated Interferon/Ribavirin
PSI-7977 + Pegylated Interferon/Ribavirin
12-week Daclatasvir + Pegylated Interferon/Ribavirin
Danoprevir + Pegylated Interferon/Ribavirin
Web Design and Development by